Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer

Yoko Tsukita; Takehiro Tozuka; Kohei Kushiro; Shinobu Hosokawa; Toshiyuki Sumi; Mao Uematsu; Osamu Honjo; Ou Yamaguchi; Tetsuhiko Asao; Jun Sugisaka; Go Saito; Jun Shiihara; Ryo Morita; Seigo Katakura; Takehiro Yasuda; Kakeru Hisakane; Eisaku Miyauchi; Satoshi Morita; Kunihiko Kobayashi; Hajime Asahina

doi:10.1001/jamaoncol.2023.6277

Abstract

Immune checkpoint inhibitor (ICI) plus chemotherapy combination treatment (ICI-chemotherapy) is now a standard treatment for non-small cell lung cancer (NSCLC) without targetable oncogene alterations, but there are few data on ICI-chemotherapy for patients 75 years and older.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tsukita et al. (2024) studied this question.

synapsesocial.com/papers/68e7541bb6db6435876cbda4 https://doi.org/10.1001/jamaoncol.2023.6277

View Full Paper

Ask AI

Bookmark

Share

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer

Abstract

Discussion

Cite This Study

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer

Abstract

Discussion

Cite This Study

Keep reading

Keep reading